- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05691361
Safety, Tolerability, PK, PD of ADX-324 in Healthy Volunteers and Hereditary Angioedema Patients
March 28, 2024 updated by: ADARx Pharmaceuticals, Inc.
A Phase 1, Randomized, Placebo-Controlled, Double Blind Single Ascending Dose Study in Healthy Volunteers and an Expansion Cohort in Patients With Hereditary Angioedema to Evaluate the Safety, Tolerability, PK and PD of ADX-324
The first-in-human Phase 1 study will evaluate the safety, tolerability, pharmacokinetics (PK) and pharmacodynamics (PD) of ADX-324 in healthy volunteers (HV) and in patients with Hereditary Angioedema (HAE).
Study Overview
Status
Recruiting
Conditions
Intervention / Treatment
Detailed Description
The clinical study described in this protocol is a Phase 1, single-center study evaluating safety, tolerability, PK, and PD of ADX-324.
The study consists of 2 parts:
- Randomized, double-blind, placebo-controlled, parallel group, single ascending dose (SAD) in HV with up to 6 dose cohorts. For SAD cohorts and planned dosing; and,
- Expansion cohort in participants with Hereditary Angioedema (HAE) at selected dose from Part A and will be open label.
Study Type
Interventional
Enrollment (Estimated)
53
Phase
- Phase 1
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Contact
- Name: CMAX Reception
- Phone Number: +610870887900
- Email: Jane.kelly@cmax.com.au
Study Locations
-
-
South Australia
-
Adelaide, South Australia, Australia, 5000
- Recruiting
- CMAX Clinical Research
-
Contact:
- CMAX Reception
- Phone Number: +61 0870887900
- Email: jane.kelly@cmax.com.au
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years to 55 years (Adult)
Accepts Healthy Volunteers
Yes
Description
Part A - HV
Inclusion Criteria:
- Male and female adults 18 to 55 years old
- Body mass index (BMI) between 18 and 30 kg/m2
- Contraception use by men or women should be consistent with local regulations regarding the methods of contraception for those participating in clinical studies
- Willing and able to provide informed consent and comply with all study visits
Exclusion Criteria:
- Any significant medical history
- Active malignancy and/or history of malignancy in the past 5 years
- History of liver disease, Gilbert's syndrome, or abnormal liver function test
- Estimated creatinine clearance <60 mL/min or serum creatinine > 1.5-fold upper limit of normal.
- Any active infection or acute illness
- Major surgery or significant traumatic injury occurring within 3 months
- Have any other conditions that, in the opinion of the Investigator or Sponsor, would make the participant unsuitable for inclusion, or could interfere with the participant participating in or completing the study.
- Positive serology tests (HepB, Hep C, HIV)
- Use of any prescription, vaccines, supplements/vitamins, or over-the counter medication
- Treatment with another investigational product within 30 days prior to the first study drug administration
- Known any clinically significant allergic reactions which, in the opinion of the Investigator, would interfere with the volunteer's ability to participate in the study
- Known hypersensitivity to any of the study drug ingredients.
- Pregnancy, intent to become pregnant during the course of the study, or lactating women
Part B - HAE
Inclusion Criteria:
- Male and female ≥18 years old, inclusive, at the time of signing the PICF
- Confirmed diagnosis of HAE Types I or II
- Evidence of an average of (at least) one HAE attack per month
- Participants must have access to, and the ability to use, acute medication(s) to treat angioedema attacks.
- Body mass index (BMI) between 18 and 30 kg/m2
- Contraception use by men or women should be consistent with local regulations regarding the methods of contraception for those participating in clinical studies
- Willing and able to provide informed consent and comply with all study visits
Exclusion Criteria:
- Concurrent diagnosis of any other type of chronic angioedema
- History of clinically significant arterial or venous thrombosis, or current history of a clinically significant prothrombotic risk.
- Any significant medical history
- Active malignancy and/or history of malignancy in the past 5 years
- Any active infection or acute illness, inclusive of cold/flu or COVID-19, within 30 days prior to the first study drug administration.
- Major surgery or significant traumatic injury occurring within 3 months prior to signature of the PICF
- Have any other conditions that, in the opinion of the Investigator or Sponsor, would make the participant unsuitable for inclusion, or could interfere with the participant participating in or completing the study.
- Positive serology tests for human immunodeficiency virus (HIV), hepatitis B surface antigen (HBsAg), or hepatitis C virus (HCV).
- Use of C1-INH products, androgens, antifibrinolytics or other small molecule medications for routine prophylaxis within four half-lives prior to screening
- Must have documented evidence of medical history of HAE attacks
- Use of any prescription, vaccines, supplements/vitamins, or over-the counter medication (with the exception of oral contraceptives) within 7 days prior to the first study drug administration.
- Treatment with another investigational product or biologic agent within 30 days prior to the study drug administration
- History or presence of alcohol abuse or drug use within 30 days prior to the first study drug administration and throughout the study.
- Blood donation of 50 to 499 mL within 30 days prior to the first study drug administration or of >499 mL within 60 days prior to the first study drug administration.
- Pregnancy, intent to become pregnant during the course of the study, or lactating women.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Sequential Assignment
- Masking: Quadruple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: PART A - Active ADX-324 administered to HV
For each cohort in Part A (SAD), 8 participants will be randomized in a 3:1 ratio; 6 participants to active (ADX-324): 2 participants to control (matched placebo).
Randomization will be on Day 1.
Initially, 2 sentinel participants (1 active and 1 placebo) will be randomized and dosed.
The sentinel participants will be evaluated for safety.
The investigator's assessment and the independent medical monitor will decide upon the randomization and dosing of the 6 remaining participants (5 active and 1 placebo) according to the randomization schedule.
|
siRNA duplex oligonucleotide
Other Names:
|
Placebo Comparator: PART A- Placebo administered to HV
For each cohort in Part A (SAD), 8 participants will be randomized in a 3:1 ratio; 6 participants to active (ADX-324): 2 participants to control (matched placebo).
Randomization will be on Day 1.
Initially, 2 sentinel participants (1 active and 1 placebo) will be randomized and dosed.
The sentinel participants will be evaluated for safety.
The investigator's assessment and the independent medical monitor will decide upon the randomization and dosing of the 6 remaining participants (5 active and 1 placebo) according to the randomization schedule.
|
saline
Other Names:
|
Experimental: PART B - ADX-324 administered to HAE participants
This will be initiated at the dose level determined by the Safety Review Committee from SAD in HVs.
The treatment of HAE participants is an open-label study.
|
siRNA duplex oligonucleotide
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Safety in Healthy Volunteers
Time Frame: 365 days
|
To evaluate the safety and tolerability of ADX-324 in HVs by incidence, relationship, and severity of adverse events and serious adverse events
|
365 days
|
Safety in Healthy Volunteers
Time Frame: 365 days
|
To evaluate the safety and tolerability of ADX-324 in HVs by change in baseline electrocardiogram (ECG) parameters (PR, QRS, QT, and QTcF intervals)
|
365 days
|
Safety in Hereditary Angioedema
Time Frame: 365 days
|
To evaluate the safety and tolerability of ADX-324 in HAE by incidence, relationship, and severity of adverse events and serious adverse events
|
365 days
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Pharmacokinetics in Healthy Volunteers
Time Frame: 8 days
|
To characterize the Pharmacokinetics of ADX-324 in HVs by measuring the Maximum observed concentration (Cmax)
|
8 days
|
Pharmacokinetics in Healthy Volunteers
Time Frame: 8 days
|
To characterize the Pharmacokinetics of ADX-324 in HVs by measuring the Time to Cmax (Tmax)
|
8 days
|
Pharmacokinetics in Healthy Volunteers
Time Frame: 8 days
|
To characterize the Pharmacokinetics of ADX-324 in HVs by measuring the Area under the concentration-time curve from 0 to time of last quantifiable concentration (AUC0-last)
|
8 days
|
Pharmacokinetics in Healthy Volunteers
Time Frame: 8 days
|
To characterize the Pharmacokinetics of ADX-324 in HVs by measuring the Area under the concentration-time curve from 0 to infinity (AUC0-∞)
|
8 days
|
Pharmacokinetics in Healthy Volunteers
Time Frame: 8 days
|
To characterize the Pharmacokinetics of ADX-324 in HVs by measuring the Apparent terminal half-life (t½)
|
8 days
|
Pharmacokinetics in Healthy Volunteers
Time Frame: 8 days
|
To characterize the Pharmacokinetics of ADX-324 in HVs by measuring the Terminal elimination rate constant (λz)
|
8 days
|
Pharmacokinetics in Healthy Volunteers
Time Frame: 8 days
|
To characterize the Pharmacokinetics of ADX-324 in HVs by measuring the Total apparent body clearance (CL/F)
|
8 days
|
Pharmacokinetics in Healthy Volunteers
Time Frame: 8 days
|
To characterize the Pharmacokinetics of ADX-324 in HVs by measuring the Apparent volume of distribution (Vz/F)
|
8 days
|
Pharmacodynamics in Healthy Volunteers
Time Frame: 365 days
|
To characterize the PD of ADX-324 in HVs by the Change from base in plasma concentrations over time of pre Kallikrein (PKK)
|
365 days
|
Pharmacodynamics in Healthy Volunteers
Time Frame: 365 days
|
To characterize the PD of ADX-324 in HVs by the Change from base in plasma concentrations over time of Kallikrein (KK)
|
365 days
|
Pharmacokinetics in Hereditary Angioedema
Time Frame: 365 days
|
To characterize the PD of ADX-324 in HAE by Maximum observed concentration (Cmax) of ADX-324
|
365 days
|
Pharmacokinetics in Hereditary Angioedema
Time Frame: 8 days
|
To characterize the PD of ADX-324 in HAE by Time to Cmax (Tmax) of ADX-324
|
8 days
|
Pharmacokinetics in Hereditary Angioedema
Time Frame: 8 days
|
To characterize the PD of ADX-324 in HAE by Area under the concentration-time curve from 0 to time of last quantifiable concentration (AUC0-last) of ADX-324
|
8 days
|
Pharmacokinetics in Hereditary Angioedema
Time Frame: 8 days
|
To characterize the PD of ADX-324 in HAE by Area under the concentration-time curve from 0 to infinity (AUC0-∞) of ADX-324
|
8 days
|
Pharmacokinetics in Hereditary Angioedema
Time Frame: 8 days
|
To characterize the PD of ADX-324 in HAE by Apparent terminal half-life (t½)
|
8 days
|
Pharmacokinetics in Hereditary Angioedema
Time Frame: 8 days
|
To characterize the PD of ADX-324 in HAE by Terminal elimination rate constant (λz)
|
8 days
|
Pharmacokinetics in Hereditary Angioedema
Time Frame: 8 days
|
To characterize the PD of ADX-324 in HAE by Total apparent body clearance (CL/F)
|
8 days
|
Pharmacokinetics in Hereditary Angioedema
Time Frame: 8 days
|
To characterize the PD of ADX-324 in HAE by Apparent volume of distribution (Vz/F)
|
8 days
|
Pharmacodynamics in Hereditary Angioedema
Time Frame: 365 days
|
To characterize the PD of ADX-324 in HV by Change from base in plasma concentrations over time pre-kallikrein (PKK)
|
365 days
|
Pharmacodynamics in Hereditary Angioedema
Time Frame: 365 days
|
To characterize the PD of ADX-324 in HAE by Change from base in plasma concentrations over time kallikren (KK)
|
365 days
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Investigators
- Principal Investigator: Nicholas Farinola, MD, CMAX Clinical Research Pty Ltd
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
December 14, 2022
Primary Completion (Estimated)
January 2, 2025
Study Completion (Estimated)
December 26, 2025
Study Registration Dates
First Submitted
December 16, 2022
First Submitted That Met QC Criteria
January 10, 2023
First Posted (Actual)
January 20, 2023
Study Record Updates
Last Update Posted (Actual)
March 29, 2024
Last Update Submitted That Met QC Criteria
March 28, 2024
Last Verified
March 1, 2024
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Cardiovascular Diseases
- Vascular Diseases
- Skin Diseases
- Immunologic Deficiency Syndromes
- Immune System Diseases
- Hypersensitivity, Immediate
- Genetic Diseases, Inborn
- Skin Diseases, Vascular
- Hypersensitivity
- Urticaria
- Hereditary Complement Deficiency Diseases
- Primary Immunodeficiency Diseases
- Angioedema
- Angioedemas, Hereditary
Other Study ID Numbers
- ADX-324-101
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
UNDECIDED
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Hereditary Angioedema
-
Pharvaris Netherlands B.V.Active, not recruitingHereditary Angioedema | Hereditary Angioedema Type I | Hereditary Angioedema Type II | Hereditary Angioedema Types I and II | Hereditary Angioedema Attack | Hereditary Angioedema With C1 Esterase Inhibitor Deficiency | Hereditary Angioedema - Type 1 | Hereditary Angioedema - Type 2 | C1 Esterase Inhibitor... and other conditionsUnited States, Poland, Germany, Austria, Bulgaria, Canada, Ireland, Italy, United Kingdom
-
Pharvaris Netherlands B.V.CompletedHereditary Angioedema | Hereditary Angioedema Type I | Hereditary Angioedema Type II | Hereditary Angioedema Types I and II | Hereditary Angioedema Attack | Hereditary Angioedema With C1 Esterase Inhibitor Deficiency | Hereditary Angioedema - Type 1 | Hereditary Angioedema - Type 2 | C1 Esterase Inhibitor... and other conditionsBulgaria, United States, Spain, Israel, Germany, Canada, Czechia, France, Hungary, Italy, Netherlands, Poland, United Kingdom
-
Pharvaris Netherlands B.V.RecruitingHereditary Angioedema | Hereditary Angioedema Type I | Hereditary Angioedema Type II | Hereditary Angioedema Types I and II | Hereditary Angioedema Attack | Hereditary Angioedema With C1 Esterase Inhibitor Deficiency | Hereditary Angioedema - Type 1 | Hereditary Angioedema - Type 2 | C1 Esterase Inhibitor... and other conditionsUnited States
-
Pharvaris Netherlands B.V.RecruitingHereditary Angioedema | Hereditary Angioedema Type I | Hereditary Angioedema Type II | Hereditary Angioedema Types I and II | Hereditary Angioedema Attack | Hereditary Angioedema With C1 Esterase Inhibitor Deficiency | Hereditary Angioedema - Type 1 | Hereditary Angioedema - Type 2 | C1 Esterase Inhibitor... and other conditionsUnited States, Bulgaria, Czechia, Hungary, Spain, France, Germany, Poland, Canada, Israel
-
CENTOGENE GmbH RostockCompletedHereditary Angioedema | Hereditary Angioedema Type I | Hereditary Angioedema Type II | C1 Esterase Inhibitor Deficiency | HAE | Angio Edema | C4 Deficiency | Hereditary Angioedema Type IIITurkey, Armenia, Georgia, India, Peru, Poland, Romania
-
HAE Global Registry FoundationRecruitingHereditary Angioedema Type I and IIItaly
-
KalVista Pharmaceuticals, Ltd.CompletedHereditary AngioedemaUnited States, Austria, Czechia, Germany, Hungary, Italy, Netherlands, North Macedonia, Poland, United Kingdom
-
Prothya BiosolutionsCompletedHereditary Angioedema Type I | Angioneurotic EdemaNetherlands
-
TakedaNot yet recruitingHereditary Angioedema (HAE)
-
CSL BehringRecruitingHereditary Angioedema (HAE)United States, Israel
Clinical Trials on ADX-324
-
Sidney Kimmel Comprehensive Cancer Center at Johns...National Cancer Institute (NCI); BerGenBio ASATerminatedBrain and Central Nervous System TumorsUnited States
-
Sage TherapeuticsCompletedEssential TremorUnited States
-
Q32 Bio Inc.RecruitingAtopic DermatitisUnited States
-
Aldeyra Therapeutics, Inc.Completed
-
Q32 Bio Inc.CompletedSafety IssuesAustralia
-
Aldeyra Therapeutics, Inc.ORA, Inc.Completed
-
Sage TherapeuticsBiogenActive, not recruiting
-
Aldeyra Therapeutics, Inc.WithdrawnNephrotic SyndromeUnited States
-
Aldeyra Therapeutics, Inc.CompletedPlaque PsoriasisUnited States